News

51. Clinical Hold Removed For Helix Biopharma Corp.'s Topical Interferon Alpha-2B Phase II/III Efficacy Trial IND Application 11/14/2011
    Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that the “clinical hold” on its investigational new drug (“IND”) application for its Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial has been removed by the United States Food and Drug Administration (“FDA”).
52. Cempra Announces Comparable Efficacy Of Oral Solithromycin (CEM-101) Compared With Levofloxacin In Phase II Clinical Trial In Patients With Community-Acquired Bacterial Pneumonia (CABP) 9/20/2011
    Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).
53. Mark Sneff Named Vice President, Human Resources At Premier Research Group 8/3/2011
    Premier Research Group Limited announces the appointment of Mark P. Sneff to the position of Vice President, Human Resources.
54. Cetero Research Responds To FDA Untitled Letter 8/1/2011
    Cetero Research, the leading provider of early phase research services, remains fully committed to maintaining the quality and integrity of the data collected in each of its facilities, including the Houston, TX, bioanalytical laboratory.
55. Adeona Plans To Commercialize wellZin™ To Reduce Symptoms Of The Common Cold 8/1/2011
    Adeona Pharmaceuticals, Inc. announced today that it has acquired exclusive access to two sets of clinical data demonstrating, with statistical significance, the safety and efficacy of a particular oral zinc formulation in reducing the duration and severity of symptoms associated with the common cold.
56. Synowledge Announces The Launch Of Regulatory Affairs Services 7/24/2011

    Synowledge, LLC, a market leader in pharmacovigilance and related IT services for pharmaceutical and biotechnology companies, is pleased to announce the launch of its Regulatory Affairs service line.

57. IDDCR - Temple School Of Pharmacy (TUSP) Life Science - Clinical Research, Pharmacovigilance Programs To Help Industry Talent Crunch In India 7/15/2011
    International Drug Discovery and Clinical Research (IDDCR) and the prestigious Temple University’s School of Pharmacy (TUSP) have joined hands in the delivery of global certificate programs to India.
58. Titan Pharmaceuticals Announces Positive Top Line Results In Confirmatory Phase 3 Trial Of Probuphine 7/15/2011
    Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced positive results from its Phase 3 placebo- and active drug-controlled confirmatory clinical study of Probuphine™, evaluating the safety and efficacy of its investigational drug in treating patients with opioid dependence.
59. ICON Announces ICONIK - An Integrated Technology Solution Providing A Single View Of Study Information 7/8/2011
    ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, recently announced ICONIK, an integrated technology solution that provides a single view of study information to both sponsor and CRO teams anytime, anywhere.